ROQ — Roquefort Therapeutics Income Statement
0.000.00%
Last trade - 00:00FinancialsSpeculativeMicro Cap
- £5.88m
- £5.88m
- £0.00m
Annual income statement for Roquefort Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | |
|---|---|
| Period Length: | 12 M |
| Source: | ARS |
| Standards: | IFRS |
| Status: | Final |
| Revenue | |
| Total Revenue | 0.001 |
| Cost of Revenue | |
| Gross Profit | -0.009 |
| Selling / General / Administrative Expenses | |
| Research And Development | |
| Unusual Expense / Income | |
| Other Operating Expenses | |
| Total Operating Expenses | 0.918 |
| Operating Profit | -0.917 |
| Net Income Before Taxes | -0.917 |
| Net Income After Taxes | -0.917 |
| Net Income Before Extraordinary Items | |
| Net Income | -0.917 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |
| Income Available to Common Shareholders Including Extraordinary Items | |
| Diluted Net Income | -0.917 |
| Diluted Weighted Average Shares | |
| Basic EPS Including Extraordinary Items | |
| Diluted EPS Including Extraordinary Items | |
| Diluted EPS Excluding Extraordinary Items | |
| Normalised Income Before Taxes | |
| Normalised Income After Taxes | |
| Normalised Income Available to Common Shareholders | |
| Diluted Normalised EPS | -0.007 |